Form 4: Arcutis CFO Sells Shares for Tax Obligations

Arcutis Biotherapeutics' SVP Chief Financial Officer, Latha Vairavan, sold 88 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Latha Vairavan, SVP Chief Financial Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported a sale of common stock.
• The transaction involved the disposition of 88 shares of common stock.
• The shares were sold on November 3, 2025, at a weighted average price of $24.7185 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Latha Vairavan beneficially owns 64,927 shares of Arcutis Biotherapeutics common stock.
• The sale was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction for tax withholding purposes related to RSU vesting, which is a neutral event and does not indicate positive or negative sentiment towards the company's performance or outlook.

Positives

• The sale was not a discretionary sale but rather to cover tax withholding obligations, which is a routine event for RSU vesting.
• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-arranged sale not based on new material non-public information.

Negatives

• No specific negatives are identified as this is a routine, non-discretionary transaction.

Risks

• No risks are mentioned in this Form 4 filing.

Future Outlook

NA

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Industry Context

Insider transactions, particularly those related to tax withholding for RSU vesting, are common and routine events for executives in publicly traded companies. These sales are generally not interpreted as a signal of management's sentiment regarding the company's future performance, especially when conducted under a Rule 10b5-1 plan.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary sale for tax purposes and not indicative of a change in management's confidence.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Latha Vairavan, SVP Chief Financial Officer, Rule 10b5-1